Aflibercept submitted for fourth indication in EU

Article

Bayer HealthCare has applied to the EMA for marketing authorization of aflibercept solution for injection for the treatment of patients with visual impairment caused by macular oedema secondary to BRVO.

Bayer HealthCare has applied to the European Medicines Agency (EMA) for marketing authorization of aflibercept solution for injection (EYLEA) for the treatment of patients with visual impairment caused by macular oedema secondary to branch retinal vein occlusion (BRVO).

Aflibercept solution for injection into the eye is approved for the treatment of patients with neovascular age-related macular degeneration and the treatment of visual impairment caused by macular oedema secondary to central retinal vein occlusion. Bayer has previously filed for marketing authorization for the treatment of diabetic macular oedema (DME).

The EMA submission is based on the positive results from the Phase 3 VIBRANT trial, a double-masked, randomized, active-controlled study of patients with macular oedema secondary to BRVO. In the VIBRANT study, 53% of patients who received aflibercept solution for injection 2 mg monthly gained at least 15 letters (equivalent to three lines) in best corrected visual acuity (BCVA) from baseline at week 24, compared to 27% of patients who received laser. In addition, the patients who received aflibercept solution for injection achieved a 17.0 letter mean improvement over baseline in BCVA compared to a 6.9 letter mean improvement in patients who received laser.

Aflibercept solution for injection into the eye has been approved in more than 70 countries for the treatment of patients with neovascular age-related macular degeneration and nearly 60 countries for the treatment of visual impairment caused by macular oedema secondary to central retinal vein occlusion (CRVO).

Regulatory submissions have been made in Europe, Japan, Asia Pacific, Latin America and the US for the treatment of diabetic macular oedema (DME), and for BRVO in the US. Approval is being sought in Japan and Asia Pacific, for the treatment of choroidal neovascularization secondary to pathologic myopia (myopic CNV).

For more details visit the company's website.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.